Joint Venture27 Dec 2025, 12:01 pm
Aurobindo Pharma Subsidiary Terminates Agreement with BioFactura Inc., USA
AI Summary
Aurobindo Pharma Ltd. announced that Curateq Biologics Private Limited, a wholly owned subsidiary, has mutually agreed to terminate its agreement with BioFactura Inc., USA. The agreement was related to the commercialization of BFI-751, a proposed ustekinumab biosimilar product. This decision aligns with CuraTeQ’s strategic portfolio prioritisation and is not expected to have a significant impact on the company’s overall biosimilars strategy.
Key Highlights
- Aurobindo Pharma subsidiary terminates agreement with BioFactura Inc., USA
- Agreement related to BFI-751, a proposed ustekinumab biosimilar product
- Termination aligns with CuraTeQ’s strategic portfolio prioritisation
- Not expected to have a significant impact on the company’s overall biosimilars strategy
- Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015